COLO B Coloplast A/S Class B

Announcement no. 11/2018 - Paul Marcun to join Coloplast A/S Executive Management as Executive Vice President, Chronic Care

Announcement no. 11/2018 - Paul Marcun to join Coloplast A/S Executive Management as Executive Vice President, Chronic Care

NASDAQ Copenhagen

12 November 2018

Announcement no. 11/2018

Paul Marcun to join Coloplast A/S Executive Management as Executive Vice President, Chronic Care

Today, Coloplast announces that Paul Marcun will join Coloplast’s Executive Management as Executive Vice President, Chronic Care in mid-January 2019. Paul takes over from Kristian Villumsen who will as of December 4th assume the role as President and CEO of Coloplast. As Executive Vice President, Chronic Care Paul will be responsible for Global Marketing, the sales regions and the innovation pipeline within Ostomy Care and Continence Care.

Following Paul’s appointment, Coloplast’s Executive Management will as of mid-January consist of four members, Kristian Villumsen, President & CEO, Anders Lonning-Skovgaard, EVP & CFO, Allan Rasmussen, EVP Global Operations and Paul Marcun, EVP Chronic Care.  

About Paul Marcun 

Paul Marcun has around 20 years’ experience in the medtech industry. Paul first joined Coloplast in 2015 and has been part of Coloplast A/S’ management team for more than 3 years as Senior Vice President, Emerging Markets. Prior to joining Coloplast A/S, Paul served as President Eastern Europe, Middle East, Africa & India at Stryker International and Vice President Ortho-Clinical Diagnostics and Vice President Ethicon Endo Surgery & Advanced Sterilization Products for Johnson & Johnson. Paul Marcun recently served as President of Surgical Workflows at Getinge.

Paul holds a Bachelor of Veterinary Science (Hons.) from the University of Melbourne and a Master of Business Administration from the University of Technology in Sydney. Paul is an Australian and British citizen and was born in 1966.  

Kind regards,

Coloplast A/S

Lars Rasmussen, President & CEO

Attachment

EN
12/11/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

Coloplast AS: 1 director

A director at Coloplast AS bought 2,150 shares at 463.200DKK and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

 PRESS RELEASE

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående p...

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående personers handel med Coloplast-aktier Se venligst vedlagte pdf.   Vedhæftet fil

 PRESS RELEASE

Coloplast A/S - Trading in Coloplast shares by board members, executiv...

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons Please see enclosed pdf.   Attachment

 PRESS RELEASE

Coloplast udnævner Gavin Wood som ny CEO

Coloplast udnævner Gavin Wood som ny CEO Selskabsmeddelelse nr. 3/2026 Intern viden Coloplast udnævner Gavin Wood som ny CEO Det er med glæde, at Coloplasts bestyrelse kan annoncere udnævnelsen af Gavin Wood som ny CEO fra den 1. maj 2026. Gavin Wood afløser Lars Rasmussen, der har været midlertidig CEO siden den 5. maj 2025. Gavin Wood har i to årtier bestredet forskellige ledelsesroller i Johnson & Johnson, senest som øverste leder for Johnson & Johnson MedTech EMEA, en forretning der omsætter for adskillige milliarder dollars og har mere end 7000 medarbejdere på tværs af tre forretnin...

 PRESS RELEASE

Coloplast appoints Gavin Wood as new CEO

Coloplast appoints Gavin Wood as new CEO Announcement no. 3/2026 Inside information Coloplast appoints Gavin Wood as new CEO The Coloplast Board of Directors is pleased to announce the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-do...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch